Alicia Morgans

25PUBLICATIONS

201CO-AUTHORS

Predictive and prognostic markersAnimal behaviourCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (25)

Sort by Publication Date:

|Jul 08, 2026

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

|Mar 26, 2026

Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy-Related Vasomotor Symptoms.

Daniel Sentana-Lledo, Alicia K Morgans

|Mar 25, 2026

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Emmanuel S Antonarakis, Qing Cao, Victoria Catharine

|Mar 19, 2026

Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.

Neal D Shore, Daniel J George, Nasreen Khan

|Feb 26, 2026

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Feb 12, 2026

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer.

Alicia K Morgans, Christopher J D Wallis, Susan Halabi

Pageof 5

Frequent Collaborators

Neal Shore

Andrew J Armstrong

Daniel J George

Emmanuel S Antonarakis

Oliver Sartor

Alan H Bryce

Rana R McKay

Pedro C Barata

Elisabeth I Heath

Himisha Beltran

Frequent Collaborators

Neal Shore

Andrew J Armstrong

Daniel J George

Emmanuel S Antonarakis